Gilead Sciences
-
Gilead Sciences, Inc.(GILD) Q3: EPS 2.55 USD (above forecast), Revenue 8.3B USD (above forecast)
Gilead Sciences, Inc.(GILD) Q3 EPS: 2.55 USD; Forecast 2.19 USD Revenue: 8.3B USD; Forecast 7.8B USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-10-29
-
Gilead Sciences (GILD) received its third FDA approval in less than four months, with the latest being Bixlenvo approved on August 27 for the treatment of HIV-infected individuals.
Gilead Sciences has secured three U.S. Food and Drug Administration (FDA) approvals in less than four months. The most recent, on August 27, was for Bixlenvo as a daily oral medication for the treatme
-
Gilead Sciences' Q2 revenue increased by 10% year-over-year to $7.8 billion, but due to acquisition-related R&D expenses, it recorded a loss of $8.45 per share.
Gilead Sciences (GILD) announced its second-quarter fiscal year 2026 results, with total revenue increasing by 10% year-over-year to approximately $7.8 billion, and product sales growing by 8% to $7.6
-
Analysis indicates that Walmart, McDonald's, and Gilead Sciences outperformed the S&P 500 during market downturns in 2008 and 2022.
An analysis article from Yahoo Finance points out that, against the backdrop of a potential market pullback, three US stocks—Walmart (WMT), McDonald's (MCD), and Gilead Sciences (GILD)—have demonstrat
-
Gilead Sciences, Inc.(GILD) Q3: EPS 2.55 USD (above forecast), Revenue 8.3B USD (above forecast)
Gilead Sciences, Inc.(GILD) Q3 EPS: 2.55 USD; Forecast 2.19 USD Revenue: 8.3B USD; Forecast 7.8B USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-10-29
-
Gilead Sciences (GILD) received its third FDA approval in less than four months, with the latest being Bixlenvo approved on August 27 for the treatment of HIV-infected individuals.
Gilead Sciences has secured three U.S. Food and Drug Administration (FDA) approvals in less than four months. The most recent, on August 27, was for Bixlenvo as a daily oral medication for the treatme
-
Gilead Sciences' Q2 revenue increased by 10% year-over-year to $7.8 billion, but due to acquisition-related R&D expenses, it recorded a loss of $8.45 per share.
Gilead Sciences (GILD) announced its second-quarter fiscal year 2026 results, with total revenue increasing by 10% year-over-year to approximately $7.8 billion, and product sales growing by 8% to $7.6
-
Analysis indicates that Walmart, McDonald's, and Gilead Sciences outperformed the S&P 500 during market downturns in 2008 and 2022.
An analysis article from Yahoo Finance points out that, against the backdrop of a potential market pullback, three US stocks—Walmart (WMT), McDonald's (MCD), and Gilead Sciences (GILD)—have demonstrat
- No data
Gilead Sciences
24H Trending
-
1
US airlines, Microsoft, banks, the NSA, and Apple have suffered consecutive outages, with varying causes and recovery progress
-
2
JPMorgan Chase: ConvaTec Group’s earnings update is expected to dispel market concerns over achieving its 2026 guidance
-
3
UBS expects the renminbi to strengthen to 6.25 per US dollar by the end of 2027.
-
4
White House: Trump Announces Over $17 Billion in Commercial Deals and Strategic Investments During Philippines Visit and ASEAN Summit
-
5
Medline Shareholders Raise $2.1 Billion via Share Offering, with Blackstone and Carlyle Participating
-
6
Bloomberg: U.S. Treasury prices edged up for a third consecutive day, supported by cooling risk appetite
-
7
UKMTO via Peninsula: Oil tanker attacked and catches fire 13 nm north of Khasab; fire extinguished, 1 person still missing
-
8
Korean Media: Daewoo E&C discloses delivery of immersed tube tunnel for Al Faw Grand Port to Iraq
-
9
CoinDesk: Crypto Basis Trade Yields Near Treasuries, Talos Report Says
-
10
Bloomberg: Indian Tax Officials Considering Proposal to Raise Stock Derivatives Tax and Lower Stock Transaction Tax
Markets Today
Recommended Reading
